437 related articles for article (PubMed ID: 11504080)
21. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
Reubi JC; Schaer JC; Waser B; Mengod G
Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterisation of human cerebral cortex somatostatin SRIF1 and SRIF2 receptors.
Piwko C; Thoss VS; Schüpbach E; Kummer J; Langenegger D; Probst A; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):161-7. PubMed ID: 9050007
[TBL] [Abstract][Full Text] [Related]
23. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
24. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.
Cervia D; Fehlmann D; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):578-87. PubMed ID: 12750875
[TBL] [Abstract][Full Text] [Related]
25. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects.
Park S; Kamegai J; Kineman RD
Neuroendocrinology; 2003 Sep; 78(3):163-75. PubMed ID: 14512709
[TBL] [Abstract][Full Text] [Related]
26. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
Buscail L; Saint-Laurent N; Chastre E; Vaillant JC; Gespach C; Capella G; Kalthoff H; Lluis F; Vaysse N; Susini C
Cancer Res; 1996 Apr; 56(8):1823-7. PubMed ID: 8620499
[TBL] [Abstract][Full Text] [Related]
27. Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers.
Reubi JC; Waser B; Mäcke H; Rivier J
J Nucl Med; 2017 Feb; 58(2):300-306. PubMed ID: 27561878
[TBL] [Abstract][Full Text] [Related]
28. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance.
Reubi JC; Schaer JC; Markwalder R; Waser B; Horisberger U; Laissue J
Yale J Biol Med; 1997; 70(5-6):471-9. PubMed ID: 9825475
[TBL] [Abstract][Full Text] [Related]
29. The elusive nature of cerebellar somatostatin receptors: studies in rat, monkey and human cerebellum.
Piwko C; Thoss VS; Probst A; Hoyer D
J Recept Signal Transduct Res; 1997; 17(1-3):385-405. PubMed ID: 9029503
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
31. Localization and pharmacological characterization of somatostatin recognition sites in the human cerebellum.
Piwko C; Thoss VS; Probst A; Hoyer D
Neuropharmacology; 1996 Jun; 35(6):713-23. PubMed ID: 8887980
[TBL] [Abstract][Full Text] [Related]
32. Transient expression of somatostatin sst2 receptors in rat cerebellar nuclei during development.
Bucharles C; Vaudry H; Leroux P
J Chem Neuroanat; 1999 May; 16(3):223-9. PubMed ID: 10422740
[TBL] [Abstract][Full Text] [Related]
33. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
34. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin receptors: clinical implications for endocrinology and oncology.
Lamberts SW; de Herder WW; van Koetsveld PM; Koper JW; van der Lely AJ; Visser-Wisselaar HA; Hofland LJ
Ciba Found Symp; 1995; 190():222-36; discussion 236-9. PubMed ID: 7587649
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.
Unger N; Serdiuk I; Sheu SY; Walz MK; Schulz S; Saeger W; Schmid KW; Mann K; Petersenn S
Clin Endocrinol (Oxf); 2008 Jun; 68(6):850-7. PubMed ID: 18031328
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of multiple somatostatin receptors in the rat cerebellum during development.
Viollet C; Bodenant C; Prunotto C; Roosterman D; Schaefer J; Meyerhof W; Epelbaum J; Vaudry H; Leroux P
J Neurochem; 1997 Jun; 68(6):2263-72. PubMed ID: 9166718
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features.
Siehler S; Zupanc GK; Seuwen K; Hoyer D
Neuropharmacology; 1999 Mar; 38(3):449-62. PubMed ID: 10219983
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
